



# ***Divi's Laboratories Limited***

Date: November 14, 2025

To  
The Secretary  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra-Kurla Complex, Bandra (East)  
Mumbai – 400 051

To  
The Secretary  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai – 400 001

Trading Symbol: **DIVISLAB**

Scrip Code: **532488**

Dear Sir/ Madam,

**Sub: US-FDA Inspection of Company's Unit-I manufacturing facility at Lingojigudem Village, Yadadri Bhuvanagiri district, Telangana, India**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform that the Company's Unit-I facility at Lingojigudem Village, Choutuppal Mandal, Yadadri Bhuvanagiri district, Telangana, has been inspected by the US Food and Drug Administration (US-FDA) from November 10, 2025 to November 14, 2025. This inspection was a general cGMP inspection by the US-FDA. The inspection has been concluded with no 483 observations.

This is for your information and records.

Thanking you,

Yours faithfully,  
For **Divi's Laboratories Limited**

**M. Satish Choudhury**  
**Company Secretary & Compliance Officer**